Companies · Biotechnology

Radicle Science, Inc.

DEL MAR · Biotechnology

Diligence memoA one-page analyst read on Radicle Science, Inc. — recommendation, valuation, rhythm, risks.
$6.0M
Total raised · real
1
Rounds
2.1×
Latest step-up
Top 54%
Sector rank · raised
Series A
Latest stage · inferred · Thu Dec 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time)

Radicle Science, Inc. looks under-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.59× the median modeled value of Series A Biotechnology companies in 2019–2021 (216 peers) — value vs value, same stage and era.
Dormant
  • Last raise 4.5 yr ago; this sector typically re-raises about every 14 months.
  • Only one round on record and long silent — often defunct, acquired, or gone quiet.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Radicle Science, Inc. is one of 4293 Biotechnology companies tracked from DEL MAR. By capital raised it ranks mid-pack (ahead of 47% of sector peers), and mid-pack by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
23
Investors (latest)
2020
Year incorporated
2021-12-23
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$50M$100M$150M$200MSeed · 2021-12-23 Raised $2.9M (real) Modeled valuation $56M (est)$2.9M$56MSeed2021Series A · 2021-12-23 Raised $6.0M (real) Modeled valuation $106M (est)$6.0M$106MSeries A2021+$6.0MCumulative $8.9M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Seed$2.9M · 2021
Series A$6.0M · 2021

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 67%.

Modeled valuation trajectory
$106.4M
Base estimate est.
$6.5M
Conservative case
$411.4M
Upside case
$27.3M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Aa $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Seed · modeled $55.9M · 2021-12-232021Series A · modeled $106.4M · 2021-12-232021
Model inputs · modeled:benchmark-stage-stepup-v1
22%
Dilution assumption
Implied ownership sold in the financing.
44%
Survival probability
24% low · 60% high
1.62×/yr
Annual markup
2.04×/yr upside case
4.5 yr
Elapsed time used
4.5 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
0 mo
Avg between rounds
Capital velocity
4.5 yr
On record since
2021
First round
2
Rounds on file
How it compares to the market

Benchmarked against 4293 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 0.8× of median
This company$6.0M
Sector median$7.2M
Latest round — vs other Series A rounds in sector (real $, this stage) 1.1× above median
This company$6.0M
Sector median$5.4M
Modeled value — vs sector median (estimate, all stages) 1.7× above median
This company$106.4M
Sector median$64.2M

Raised more than 47% of sector peers (real $). Modeled value above 60% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #161 of 216.

This companyCohort peer
$10.0M$100.0M$1.0B$1.0M$10.0M$100.0MCapital raised (log)TRACT Therapeutics, Inc. · Series A Raised $15.0M · modeled $542.3M (est)TechAccel, LLC · Series A Raised $15.0M · modeled $542.3M (est)Arrakis Therapeutics, Inc. · Series A Raised $28.2M · modeled $542.3M (est)Trident Labs, Inc. · Series A Raised $14.0M · modeled $506.1M (est)Meissa Vaccines Inc · Series A Raised $15.2M · modeled $503.1M (est)Vibe Bioscience Ltd. · Series A Raised $13.9M · modeled $501.1M (est)Trovagene, Inc. · Series A Raised $45.3M · modeled $488.0M (est)Taiga Biotechnologies, Inc. · Series A Raised $37.9M · modeled $485.3M (est)Equinox, Inc. · Series A Raised $34.7M · modeled $485.2M (est)Aruna Biomedical Inc · Series A Raised $22.4M · modeled $480.5M (est)Vibe Bioscience Corp · Series A Raised $13.7M · modeled $476.8M (est)Adarza BioSystems, Inc. · Series A Raised $31.5M · modeled $461.9M (est)Radicle Science, Inc. (this company) Raised $6.0M · modeled $106.4M (est)Radicle Science, Inc.
CompanyStageRaised · realValue · estvs peer med.
TRACT Therapeutics, Inc.Series A$15.0M$542.3M3.00×
TechAccel, LLCSeries A$15.0M$542.3M3.00×
Arrakis Therapeutics, Inc.Series A$28.2M$542.3M3.00×
Trident Labs, Inc.Series A$14.0M$506.1M2.80×
Meissa Vaccines IncSeries A$15.2M$503.1M2.78×
Vibe Bioscience Ltd.Series A$13.9M$501.1M2.77×
Trovagene, Inc.Series A$45.3M$488.0M2.70×
Taiga Biotechnologies, Inc.Series A$37.9M$485.3M2.68×
Equinox, Inc.Series A$34.7M$485.2M2.68×
Aruna Biomedical IncSeries A$22.4M$480.5M2.66×
Vibe Bioscience CorpSeries A$13.7M$476.8M2.64×
Adarza BioSystems, Inc.Series A$31.5M$461.9M2.56×
Radicle Science, Inc. this companySeries A$6.0M$106.4M0.59×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Seed$2.9M2021-12-23$14.3M$55.9M90%
Series A$6.0M2021-12-23$27.3M$106.4M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Seed$2.9M2021-12-23
    • First recorded raise — entered as Seed.
    • 23 investors on this round.
  2. Series A$6.0M2021-12-23
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 2.1× larger than the prior — scaling up.
    • 23 investors on this round.
Intelligence
Modeled next raise
$12.6M
Modeled next size est.range $8.2M$20.2M
2.1×
Last step-up
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Bruce Wood Hansen2021-12
Jeffrey Ming-chie Chen2021-12
Pelin Wood Thorogood2021-12
Ted Wood Roth2021-12
Registry & provenance

Radicle Science, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1903071
SEC CIK
2020
Incorporated
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Amberstone Biosciences, Inc.BiotechnologySeries A$6.0M$112.7Msame sector · same stage
Lazarus 3D, Inc.BiotechnologySeries A$6.0M$93.6Msame sector · same stage
Sinaptic Holdings, LLCBiotechnologySeries A$5.6M$88.0Msame sector · same stage
DNAlite Therapeutics, Inc.BiotechnologySeries A$5.6M$87.1Msame sector · same stage
Markman Biologics CorpBiotechnologySeries A$6.5M$103.9Msame sector · same stage
CorriXR Therapeutics, Inc.BiotechnologySeries A$6.5M$90.1Msame sector · same stage
Redesign Science IncBiotechnologySeries A$6.7M$112.0Msame sector · same stage
CoRISMA MCS Systems, Inc.BiotechnologySeries A$5.2M$112.0Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Ra Medical Systems, Inc.BiotechnologySeries C$116.1M87%
Ravgen, Inc.BiotechnologySeed$67.6M86%
Rakuten Medical, Inc.BiotechnologySeries D+$17.7M86%
Resolute Science, Inc.BiotechnologySeed$4.7M86%
Resolys Bio, Inc.BiotechnologySeries A$361.5M86%
Recombinetics, IncBiotechnologySeries B$1.3B85%
Regenimo Biosciences, Inc.BiotechnologySeed$4.6M84%
Reprogram Biosciences, Inc.BiotechnologyPre-Seed$2.7M84%
Frequently asked
How much funding has Radicle Science, Inc. raised?
Radicle Science, Inc. has raised approximately $6.0M in disclosed capital across 1 recorded financing round, aggregated from public filings.
What is Radicle Science, Inc.'s estimated valuation?
Provath's modeled valuation for Radicle Science, Inc. is approximately $106.4M (modeled range $6.5M–$411.4M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Radicle Science, Inc. at?
Radicle Science, Inc.'s latest modeled financing stage is Series A. Its most recent recorded round closed around Thu Dec 23.
What does Radicle Science, Inc. do and where is it based?
Radicle Science, Inc. operates in the Biotechnology sector, based in DEL MAR.
Explore related

See where Radicle Science, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Radicle Science, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.